Skip to main content
Equibles
ISRG logo

ISRG · Intuitive Surgical Inc

Track ISRG — free

Use ISRG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ISRG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$406.50 -5.68 (-1.38%)
S&P 500 member Nasdaq-100 member Russell 1000 member Rebalance outlook locked
Market Cap
$143.14B
Shares
353.28M
Volume · Sep 30 1.66M Avg daily vol (3M) 2.99M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$412.18 Open$411.90 Day$407.07–414.20 52W close$332.02–592.85 Avg vol 30d2.3M Short int8.1M · 2.3% float · 3.4d Short vol44% Last earningsJul 16, 2026 DataJan 2020–Sep 2026 Filing10-Q · Jul 21

Up next

Next earnings call
Oct 14, 2026 Est · unconfirmed · in 2 wks
Latest filing: 10-Q
filed Jul 21, 2026
Q2 2026 earnings call transcript
call held Jul 16, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$11.03B
Trailing 12 months
Net income (TTM)
$3.14B
Trailing 12 months
Revenue growth YoY
+18.5%
Year over year
Operating margin
31.3%
Trailing 12 months
P / E (TTM)
47.3
Trailing earnings · reciprocal yield 2.1%
FCF yield
2.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$5.22B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-1.9%
Year over year · fewer shares
Price change (1Y)
-6.2%
Trailing year
Short interest
2.3%
Latest settlement · 3.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bearish Fundamentals Excellent Quant / Vol High
Market backdrop VIX 16 · calm Equity put/call 0.38
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −8%
below
Price vs 50-day avg +9%
above
RSI (14) 67
neutral
MACD trend Positive
52-week position 31%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +9%
trailing
6-month return −11%
trailing
YTD return −27%
this year
Relative strength −24%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $376 › 200d $449 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +183 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.30% of float · ▲ +5.0% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
2,267 holders — mid 3-yr range
Squeeze score 54
elevated · 0–100
Fundamentals
Excellent
Revenue growth +21%
Y/Y
Gross margin 66%
contracting
EPS growth +23%
Y/Y
Valuation P/E 46.5
rich
Buyback $4.7B
remaining
Quant / Vol
risk profile
High
Volatility 37%
annualized · 1-yr
Max drawdown −44%
past year
ATR 2.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Jul 16, 2026
Worldwide da Vinci procedure growth · 2026 13.5% – 15.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−8% Bearish
Price vs 50-day avg
+9% Bullish
RSI (14)
67 Neutral
MACD trend
Positive Bullish
52-week position
31% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $376 › 200d $449 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +183 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.30% of float · ▲ +5.0% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
2,267 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $332 Now $412 · 31% Range high $593
vs 200-day avg -8% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
% of Total da Vinci surgical system placements (under leasing) 54% Three Months Ended June 30, 2026 filing —
% of Total revenue 85% Three Months Ended June 30, 2026 filing —
da Vinci 5 systems placed 246 the three months ended June 30, 2026 filing —
da Vinci procedure volume growth 15% Three Months Ended June 30, 2026 filing —
da Vinci procedures performed 889,000 the three months ended June 30, 2026 filing —
da Vinci surgical system ASP $1.59M the three months ended June 30, 2026 filing —
da Vinci surgical systems placed 468 the three months ended June 30, 2026 filing —
IEEPA tariff refunds (product) $27.5M the second quarter of 2026 filing —
IEEPA tariff refunds (service) $8.4M the second quarter of 2026 filing —
Ion procedure volume growth 36% Three Months Ended June 30, 2026 filing —
Ion procedures performed 47,900 the three months ended June 30, 2026 filing —
Ion systems placed 55 the three months ended June 30, 2026 filing —
Lease Buyouts revenue $56M Three Months Ended June 30, 2026 filing —
Operating lease revenue $262M Three Months Ended June 30, 2026 filing —
OUS da Vinci procedure growth 20% Three Months Ended June 30, 2026 filing —
Product gross profit margin 67.9% Three Months Ended June 30, 2026 filing —
Service gross profit margin 67.2% Three Months Ended June 30, 2026 filing —
Total da Vinci surgical system placements under leasing arrangements 264 Three Months Ended June 30, 2026 filing —
Total Ion system placements under leasing arrangements 31 Three Months Ended June 30, 2026 filing —
Total recurring revenue $2.47B Three Months Ended June 30, 2026 filing —
U.S. da Vinci procedure growth 12% Three Months Ended June 30, 2026 filing —
Variable lease revenue $169M Three Months Ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ISRG
Intuitive Surgical Inc
this stock
$143.14B -27.2% +20.5% 46.5 2.3%
BDX
Becton Dickinson & Co
 $49.57B — +8.2% — 4.2%
MDLN
Medline Inc.
 $45.62B -16.7% +11.5% — 3.1%
RMD
Resmed Inc
 $32.02B -7.5% +13.4% 21.3 9.8%
ALC
Alcon Inc
 $31.52B -17.0% +10.5% — 3.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
2,267
% held
89.2%
Net QoQ
+12.7M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,226
View
Short & Settlement
Short Interest Rising
Shares short
8.1M
Days to cover
3.4d
Change
+389.0K sh
View
Short Volume
Short vol %
44%
As of
Sep 30, 2026
Short Total
View
Fails to Deliver
FTD shares
20
Value
$7.5K
As of
Aug 21, 2026
View
Off-Exchange
Off-exchange %
44.2%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$10.1B
Net income (FY)
$2.9B
EPS diluted
$7.87
View
Buybacks
Authorized
$17.4B
Remaining
$4.7B
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 9, 2026
This year
13
View
Proposed Sales
Value
$823.2K
Shares
2.2K
Filed
Sep 15, 2026
View
Earnings & Events
Earnings Calls
Last call
Sep 9, 2026
View

Performance

5D 20D 120D MTD YTD
ISRG +2.5% +9.4% -10.8% +9.4% -27.2%
SPY -1.2% -0.4% +13.1% -0.4% +12.1%
vs SPY +3.7% +9.7% -23.9% +9.7% -39.3%

Capital returns

Buyback program · as of Jun 30, 2026
Authorized
$17.40B
Spent (derived)
$12.70B
Remaining
$4.70B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1035267 CUSIP 46120E602 13F (30d) 37 filings 27 filers Visit website Investor relations